1. Introduction {#s0005}
===============

Osteosarcoma is the most common primary bone malignancy, with an age-standardized incidence rate of 2.9 per 1 million men and 2.2 per 1 million women \[[@bb0005]\]. Nearly 90% of cases are classified as high-grade osteosarcoma (HOS) at the time of diagnosis \[[@bb0010]\]. Although the implementation of neoadjuvant and adjuvant chemotherapies and limb salvage surgeries has gradually increased the survival rate of HOS, the overall survival rate has not increased significantly over the past 30 years \[[@bb0015],[@bb0020]\]. The 5-year overall survival rate for HOS ranges from 45% to 75% \[[@bb0025]\]. Although aggressive treatment plans, including multi-cycle treatments and adjuvant chemotherapies, are beneficial for patients who are likely to exhibit poor survival, not all HOS patients benefit from these treatments \[[@bb0030],[@bb0035]\]. If patients with poor survival could be identified preoperatively, personalized treatment plans could be helpful for decision support for these patients. Therefore, there is a critical need to identify patients who are more likely to experience poor survival and thus benefit from additional therapy. Several clinical factors, such as age \[[@bb0040]\], tumor volume \[[@bb0045]\], stage \[[@bb0025],[@bb0050]\], histologic subtype \[[@bb0055]\] and pathological fractures \[[@bb0060]\] have been associated with treatment outcome \[[@bb0065],[@bb0070]\]. Nevertheless, a preoperative prognostic model for survival prediction has not yet been constructed. To address this issue, we built a reliable model to predict 5-year survival status at the time of diagnosis in HOS.

Recently, rapid developments in diagnostic imaging have become essential in the context of osteosarcoma decision-making in clinical practice; this especially includes computed tomography (CT) and magnetic resonance imaging (MRI). Notably, CT images can be used to determine tumor size, location, and migration status \[[@bb0075]\]. Radiomics is an emerging field that converts medical images into a high-dimensional mineable feature space via high-throughput quantitative feature extraction \[[@bb0080],[@bb0085]\]. Previous radiomics studies have shown that objective and quantitative radiomics features might serve as prognostic imaging biomarkers \[[@bb0090]\]. In the past 5 years, radiomics has been used in multiple aspects of the clinical assessment of tumors, including detection, diagnosis, curative effect, and prognosis \[[@bb0095], [@bb0100], [@bb0105], [@bb0110]\]. These studies demonstrated the feasibility of developing a nomogram with radiomics features to predict 5-year survival status for patients with HOS.

Hence, this study aimed to develop and validate a survival prediction nomogram that incorporates both a radiomics signature and clinical risk factors at the time of diagnosis for individualized prediction of survival in patients with HOS. In addition, we compared prediction performance between the nomogram and a model built with clinical factors alone. To the best of our knowledge, this is the first study that used radiomics to model survival prediction at the time of diagnosis in HOS, based on CT images.

2. Material and Methods {#s0010}
=======================

2.1. Patients {#s0015}
-------------

This retrospective study was approved by the Institutional Review Board (IRB) of our institution, which waived the requirement for signed informed consent forms. A total of 150 patients with HOS, diagnosed from January 2008 to April 2012, were enrolled in this study, in accordance with the following inclusion and exclusion criteria. The inclusion criteria were as follows: (a) patients with HOS diagnosed by multidisciplinary teams; (b) an open biopsy or CT-guided core needle biopsy, pathologically evaluated by specialized sarcoma pathologists; (c) a standard CT scan performed at the time of diagnosis; and (d) clinical characteristics available. The exclusion criteria were as follows: (a) patients who underwent chemotherapy treatment before undergoing a CT scan in our institution; (b) patients suffering from other synchronous cancers; (c) incomplete or indeterminate clinical characteristics; and (d) death by a cause other than osteosarcoma. Supplementary Data I shows the patient recruitment pathway.

Treatment options included preoperative neoadjuvant and/or adjuvant chemotherapy and surgery with the aim of achieving a wide excision (either by limb-salvage or amputation surgery). Margins were defined on the basis of Enneking\'s criteria \[[@bb0115]\]. Chemotherapeutic regimens included cisplatin, doxorubicin, and high-dose methotrexate. Most patients received neoadjuvant chemotherapy and additional adjuvant chemotherapy after surgery. The total duration of chemotherapy was at least 6--8 months.

The overall patient population was divided into two cohorts on the basis of diagnosis time: training cohort and independent validation cohort. The training cohort was used for construction of the prediction model. This cohort included 102 patients (49 males and 53 females, 8--54 years of age) who were diagnosed between January 2008 and March 2011. The independent validation cohort consisted of 48 patients (25 males and 23 females, 8--47 years of age) who were diagnosed between April 2011 and April 2012; this cohort was used to test the prediction power of the model. Patients who survived ≥5 years after treatment were classified within the survival group, whereas those who died within 5 years of the operation were classified within the non-survival group. The power test was performed to evaluate the reliability of this study by using sample size and 5-year survival rates in both training and independent validation cohorts \[[@bb0120],[@bb0125]\].

Baseline clinical data, including age, gender, tumor anatomic site, tumor stage (local/metastatic) \[[@bb0050]\], and the presence of pathological fracture (no/yes), were obtained from the Electronic Medical Record System (EMRS). All CT images were collected from the Picture Archiving and Communication System (PACS). The tumor stage and presence of pathological fracture at the time of diagnosis were determined by consensus of three experienced radiologists. The follow-up time in our study comprised every 6 weeks in the first and second years after treatment, every 3 months in the third and fourth years, and every 6 months after the fourth year. All data were collected and evaluated in April 2017 with a minimum follow-up of 5 years for all included patients.

2.2. CT Image Acquisition, Region of Interest Segmentation and Radiomics Feature Extraction {#s0020}
-------------------------------------------------------------------------------------------

CT image acquisition is described in Supplementary Data II. Image resampling and gray level quantization were performed prior to feature extraction. ITK-SNAP software was used for three-dimensional regions of interest (ROI) segmentation \[[@bb0130]\]. Texture features were extracted by using in-house developed software in MATLAB 2015b (MathWorks, Natick, MA, USA) \[[@bb0135],[@bb0140]\]. The feature pool extracted based on the 3-dimension region of interest (ROI) comprised 4 groups: (i) 6 histogram statistics features; (ii) 7 shape features; (iii) 53 texture features; and (iv) 408 wavelet features. Supplementary Data III describes the detailed features and references. The ROI was segmented by 3 orthopedists with 6 years (Orthopedist-1), 4 years (Orthopedist-2), and 4 years (Orthopedist-3) of experience in orthopedic CT interpretation. The patients in the training cohort were segmented separately by Orthopedist-1 and Orthopedist-2. The feature set based on the segmentation of Orthopedist-1 was used for model training. The feature set based on the segmentation of Orthopedist-2 was used to test the reproducibility and stability of each of the features. Patients in the validation cohort were segmented by Orthopedist-3 to test the prediction power of the trained model.

2.3. Feature Selection, Radiomics Signature Building and Validation {#s0025}
-------------------------------------------------------------------

Feature selection was performed in 3 steps to select the optimal survival-related features via the training cohort. Firstly, the reproducibility and stability of each feature was determined by calculating the correlation coefficient between feature sets, based on the segmentations of Orthopedist-1 and Orthopedist-2. We only retained stable features with an intra-class correlation coefficient \>0.8. Secondly, we used the Spearman rank correlation test to investigate the internal linear correlation between individual features. Redundant features (a linear correlation coefficient \>0.95, determined by the Spearman test) were removed \[[@bb0140]\]. Finally, the least absolute shrinkage and selection operator (LASSO) logistic regression algorithm, which is applicable for high-dimensional data reduction \[[@bb0145]\], was performed for optimal feature selection. LASSO regression reduced the coefficients for survival-unrelated variables to zero; variables with non-zero coefficients were retained. To select optimal parameters in LASSO regression, we performed 100 iterations of 10-fold cross-validation with binomial deviance minimization criteria from the training cohort \[[@bb0150]\]. Binomial deviance was used as the loss function in the model training process; the model with the minimum binomial deviance was selected. Then, a radiomics score calculation formula, defined as the radiomics signature, was generated by a linear combination of selected features multiplied by LASSO coefficients. The radiomics signature was a prediction model constructed by using the selected features; the radiomics score was calculated to reflect survival probability by using the radiomics signature for each patient. The performance of the radiomics signature was assessed by its discrimination in both training and validation cohorts, which measured how well the model could distinguish patients in the survival or non-survival groups \[[@bb0155]\]. Discrimination was demonstrated by a receiver operating characteristic (ROC) curve and the associated area under the ROC curve (AUC); sensitivity and specificity were also calculated.

2.4. Development of the Radiomics Nomogram and Clinical Model {#s0030}
-------------------------------------------------------------

Considering the potential prediction value of the clinical characteristics, a multivariable logistic regression analysis was developed by combining radiomics score and clinical characteristics based on the training cohort. The clinical characteristics included age, gender, tumor anatomic site, stage, and presence of pathological fracture. The Variance Inflation Factor (VIF) was calculated to detect the severity of multicollinearity among variables in the multiple logistic regression model \[[@bb0110]\]. The VIF was the ratio between the variance in the multiple variables mode and the variance in a model with one variable \[[@bb0095]\]; if VIF was \>10, then multicollinearity was high \[[@bb0160]\]. Then, a radiomics nomogram was developed based on the multivariate logistic regression model \[[@bb0165]\]. To compare the prediction performance of the radiomics nomogram and clinical characteristics, a clinical model was constructed separately using multivariable logistic regression analysis based on clinical factors alone.

2.5. Validation and Assessment of the Radiomics Nomogram {#s0035}
--------------------------------------------------------

The performance of the radiomics nomogram was tested in both training and validation cohorts with respect to discrimination, calibration, and clinical usefulness \[[@bb0155]\]. The AUC was measured to quantify discrimination performance; calibration measured the model\'s ability to generate predictions that were generally close to the average observed outcome. The calibration curve, representing the agreement between predicted survival probability and average actual survival probability, was plotted to assess the calibration of the radiomics nomogram. The Hosmer-Lemeshow test was applied to evaluate the goodness-of-fit of the nomogram \[[@bb0165]\]. Decision curve analysis (DCA) was used to evaluate whether the nomogram was sufficiently robust for clinical practice \[[@bb0170]\]. The net benefit was derived by calculating the difference between the true positive rate and weighted false positive rate across different threshold probabilities in the validation cohort. The "decision curve" was plotted against the threshold probability. In addition, Kaplan-Meier survival curves were plotted by using predictive survival status as the prediction factor. The patients were classified into two groups on the basis of the prediction factor: predictive survival group and predictive non-survival group. The log-rank test was used to assess the difference between survival curves from the nomogram-predicted survival and non-survival groups (p-value \<.05, 95% confidence interval \[CI\]).

2.6. Statistical Analysis {#s0040}
-------------------------

Univariate analysis for clinical factors used the Mann-Whitney U test or Chi-square test, as appropriate. Correlation was assessed by using Spearman\'s correlation rank test. Reported significance levels were two-sided, p-value \<.05. The LASSO logistic regression model was used with penalty parameter (λ) tuning, which was conducted with 10-fold cross-validation based on the binomial deviance minimum criteria. The backward search method was used with the minimum criteria of Akaike\'s information criterion (AIC) as the stopping rule for the multivariate logistic regression model \[[@bb0175],[@bb0180]\]. A detailed description of AIC is presented in Supplementary Data IV.

All statistical analyses were performed with R software (version 3.4.1; <http://www.Rproject.org>), MedCalc Statistical Software (version 15.2.2; <https://www.medcalc.org>), and PASS software (version 11.0.7; <https://www.ncss.com>). Kaplan-Meier analysis was performed by using MedCalc. The power test was calculated by using the PASS software. LASSO logistic regression analysis was performed by using the "glmnet" package. Nomograms and calibration plots were performed with the "rms" package. The Hosmer-Lemeshow test was performed by using the "generalhoslem" package. VIFs were calculated by using the "car" package. AUC analysis was conducted by using the "pROC" package. DCA was performed by using the "dca.R\" function. The two-sided statistical significance level used in this study was p-value \<.05.

3. Results {#s0045}
==========

The schematic depiction for this study is presented in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Radiomics schematic for this study.Fig. 1

3.1. Clinical Characteristics {#s0050}
-----------------------------

Clinical characteristics in the training and validation cohorts are summarized in [Table 1](#t0005){ref-type="table"}. No significant difference was observed in survival rate (p-value = .6090, Chi-square test) between the two cohorts. Survival rates in the training and validation groups were 46.07% (47/102) and 52.08% (25/48), respectively. A power of 0.9238 indicated that the sample size for training and validation in this study was sufficient.Table 1Characteristics at time of diagnosis in patients with high-grade osteosarcoma primary.Table 1Training cohort (n = 102)Independent validation cohort (n = 48)CharacteristicSurvival\
(n = 47)Non-survival\
(n = 55)p-valueSurvival\
(n = 25)Non-survival\
(n = 23)p-valueAge (years)0.47390.4371 \<15 years1924109 ≥15 years28311514Gender0.119014:1111:120.7817 Male: Female27:2022:33Tumor volume**0.0261**0.0662 Median70.94161.34108.35140.28 Range9.31, 521.9813.06, 782.1221.05, 277.0183.95, 395.01Location0.97620.7776 Distal femur29331012 Lower extremities111366 Pelvis1222 Proximal tibia6773Stage at diagnosis**0.00240.0083** Local: Metastatic46:141:1424:114:9Pathological fracture0.06300.8456 No: Yes42:540:1518:715:8Radiomics score**\<0.00010.0031** Median0.54190.36400.49220.2992 Range0.2485, 0.83670.0771, 0.75870.2280, 0.84790.0622, 0.7993[^2][^3]

3.2. Construction and Validation of Radiomics Signature {#s0055}
-------------------------------------------------------

A total of 474 features were extracted based on CT images for each patient. The heatmap showing the distribution of these radiomics features is shown in Supplementary Data V \[[@bb0095]\]. After removing survival-unrelated and redundant features, 76 features remained. Subsequently, 5 potential predictors (1:20 ratio) of the 76 features were selected via LASSO regression, based on the training cohort. Parameter (λ) selection in the LASSO model and LASSO coefficients are shown in Supplementary Data VI. The radiomics score calculation formula is presented in Supplementary Data VI, along with the selected features.

Patients in the survival group generally had higher scores than patients in the non-survival group. A significant difference in radiomics score was observed between patients in the survival and non-survival groups (0.5483 ± 0.1256 vs. 0.3860 ± 0.1678; p-value \<.0001, Mann-Whitney U test) in the training cohort. The AUC for the training cohort was 0.79 (95% CI, 0.70--0.86). The performance of the radiomics signature was confirmed by testing in the validation cohort. A significant difference in radiomics score was observed in the validation cohort (0.4935 ± 0.1564 vs. 0.3326 ± 0.2005; p-value = .0031, Mann-Whitney U test), with an AUC of 0.76 (95% CI, 0.61--0.87). Distributions of radiomics scores for the training and validation cohorts are shown in [Fig. 2](#f0010){ref-type="fig"}.Fig. 2Radiomics score for each patient in training (a) and validation (b) cohorts. Red bars indicate scores for patients in the survival group, while black bars indicate scores for patients in the non-survival group. Patients with radiomics scores \>0 were predicted to be in the survival group, while patients with radiomics scores \<0 were predicted to be in the non-survival group.Fig. 2

3.3. Development and Validation of the Radiomics Nomogram and Clinical Model {#s0060}
----------------------------------------------------------------------------

A radiomics nomogram was developed by combining the radiomics signature, stage, and tumor volume ([Fig. 3](#f0015){ref-type="fig"}a). No severe collinearity was observed in our regression model. The VIFs for radiomics score, stage, and tumor volume were 1.0799, 1.0850, and 2.9030, respectively. The clinical model was constructed with clinical characteristics of stage and tumor volume by using multivariable logistic regression analysis based on the training cohort.Fig. 3The radiomics nomogram, combining radiomics signature, stage, and tumor volume, developed in the training cohort (a). Radiomics score ranges from −2.5 to 2. Radiomics scores \< −2.5 were set to −2.5. Radiomics scores \>2 were set to 2. Tumor volume ranges from 0 to 800 cm^3^. Volumes \>800 cm^3^ were set to 800 cm^3^. ROC curves for the radiomics nomogram, radiomics signature, and clinical model in training (b) and validation (c) cohorts.Fig. 3

The calibration curve showed good agreement between the predicted probability of survival and actual probability of survival. A nonsignificant statistic (p-value = .8185, Hosmer-Lemeshow test) for the training cohort suggested no departure from the ideal fit. The AUC for the nomogram was 0.86 (95% CI, 0.77--0.92) in the training cohort. For the clinical model, an AUC of 0.79 (95% CI, 0.70--0.86) was observed. Good calibration was also observed for the probability of the 5-year survival rate in the dependent validation cohort. A nonsignificant statistic (p-value = .6431, Hosmer-Lemeshow test) showed agreement between the actual and observed survival probability with the nomogram for the dependent validation cohort. The AUC for the nomogram was 0.84 (95% CI, 0.71--0.93). The AUC for the clinical model was 0.73 (95% CI, 0.58--0.85). ROC curves for the radiomics nomogram and clinical model are presented in [Fig. 3](#f0015){ref-type="fig"}b and c for the training and validation cohorts, respectively. Detailed performances of the radiomics signature, radiomics nomogram, and clinical model are summarized in [Table 2](#t0010){ref-type="table"}.Table 2Model performance.Table 2ModelTraining cohortIndependent validation cohortSensitivitySpecificityAUC (95% CI)SensitivitySpecificityAUC (95% CI)Radiomics signature89.36%65.45%0.79 (0.70 to 0.86)88.00%65.22%0.76 (0.61 to 0.87)Radiomics nomogram82.98%80.00%0.86 (0.77 to 0.92)84.00%69.57%0.84 (0.71 to 0.93)Clinical model74.47%78.18%0.79 (0.70 to 0.86)44.00%91.30%0.73 (0.58 to 0.85)[^4]

Calibration curves for the training and independent validation cohorts are shown in [Fig. 4](#f0020){ref-type="fig"}a and b. DCAs for the radiomics nomogram in the training and independent validation cohorts are presented in [Fig. 4](#f0020){ref-type="fig"}c and d. For both training and validation cohorts, DCA curves showed that the radiomics nomogram gained more net benefits than the treat-all-patients strategy, the treat-none strategy, and the clinical model.Fig. 4Calibration curves for the radiomics nomogram in training (a) and validation (b) cohorts. The y-axis indicates the actual probability of survival; x-axis indicates the predicted probability of survival. The 45-degree black line represents the ideal prediction; red line represents the performance of the radiomics nomogram. As the red line approaches the ideal prediction line, the predictive accuracy of the nomogram increases. DCA for the radiomics nomogram and clinical model in both training (c) and independent validation cohorts (d). The y-axis indicates the net benefit; x-axis indicates threshold probability. The blue line represents net benefit of the radiomics nomogram; red line represents net benefit of the clinical model. The black line represents the hypothesis that all patients die within 5 years; gray line represents the hypothesis that no patient dies within 5 years.Fig. 4

For the patients in the non-survival group, mean survival time was 31.7 months and median survival time was 28.6 months. Kaplan-Meier curves ([Fig. 5](#f0025){ref-type="fig"}a and b) showed a significant difference between the nomogram-predicted survival and non-survival groups (p-value \<.05, log-rank test) in both training and validation cohorts.Fig. 5Kaplan-Meier curves for patients in the nomogram-predicted survival and non-survival groups from training (a) and validation (b) cohorts.Fig. 5

4. Discussion {#s0065}
=============

Preoperative prediction of 5-year survival is important for treatment planning. Previous studies solely analyzed the association between clinical factors and survival status \[[@bb0025],[@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060]\]; they did not investigate the underlying association between 5-year survival status and imaging features by using radiomics method. In this study, we developed and validated a radiomics nomogram combining radiomics score and clinical factors to evaluate survival status preoperatively; this nomogram showed better performance than the clinical model.

We chose to include axial HOS in this study because these patients were systematically referred to our multidisciplinary center, thereby reducing the risk of bias associated with investigating osteosarcoma throughout the body. Currently, it remains unclear whether there is a significant difference in survival between patients with axial and appendix tumors. Some studies suggest a potential for confounding bias when comparing these two types of HOSs \[[@bb0185]\] because of the large number of overweight, elderly patients with axial tumors \[[@bb0190]\], as well as the possibility that axial tumors might be more malignant \[[@bb0195]\]. In contrast, other studies have found no statistically significant differences in survival rates when comparing axial and appendicular HOSs \[[@bb0200]\].

Among the 5 clinical characteristics at diagnosis, the tumor stage of the osteosarcoma was included in the nomogram. The evaluation of patients with both localized and metastatic disease was a key point for 5-year survival rates for patients with osteosarcoma. A previous European Intergroup Osteosarcoma study on osteosarcoma reported a 5-year survival-rate of 56% in a cohort of 1067 localized high-grade appendicular osteosarcomas in patients ≤40 years of age. Among HOSs, we found a 48% 5-year survival-rate in our study, which was lower than in the European Intergroup Osteosarcoma\'s study; this may have occurred because our cases included patients of all ages.

In agreement with our findings, tumor volume has previously been suggested as a prognostic factor by several studies, which reported that a volume \> 150 mL led to poor prognosis and lower survival rate \[[@bb0205]\]. Other studies have shown that primary tumor size can be closely related to the anatomic site of the tumor; axial tumors tend to be larger when diagnosed, which may be related to a lower survival rate \[[@bb0065]\]. Determining tumor size has often been a difficult task because of the performance of imaging devices and the heterogeneity of tumor sizes among different bone types. Recent studies have described new methods for determining tumor size to predict prognosis in HOSs \[[@bb0070]\]. In our study, tumor volume was assessed to equalize the sites of tumors. Tumor volume was significantly different between the survival and non-survival groups in both training and validation cohorts; it could be regarded as a qualified component of the early prediction model of osteosarcoma. We suspect that this parameter may reflect the heterogeneity of osteosarcoma. Our research results constitute an improvement in the prediction accuracy of the model by combining radiomics signature and clinical factors; this is sufficiently effective to be an independent component of the nomogram.

Current literature has not yet reached a consensus regarding prognostic factors for survival in treating this difficult disease; therefore, our radiomics-based prediction nomogram for early survival prediction of osteosarcoma may allow physicians to provide a more appropriate treatment strategy for each patient. Furthermore, because our radiomics nomogram can enable personalized survival prediction for each patient, a reasonable follow-up interval could be arranged, thereby avoiding unnecessary medical resources and expenses.

Importantly, there were some limitations in our study. Firstly, the database in this study was retrospectively collected from a single center. Due to the low incidence rate of osteosarcoma, the sample size was not large. A power of 0.9238 shows that the sample size (training cohort: 102 patients; validation cohort: 48 patients) was sufficient for robust analysis, based on power analysis of the training and validation sample cohorts. Multi-center validation with a larger sample size is essential for acquiring high-level evidence for future clinical application. Secondly, since survival potential may correlate with the location of the osteosarcoma tumor, but the corresponding mechanism remains unclear, combined statistical analysis of both axial and appendicular HOS in this study may have resulted in bias. In the pre-processing of CT images from osteosarcoma tumors in different sites, tumor volumes were corrected to suppress possible biases and extend the limited database when only one site was analyzed. In future work, a series of prediction models for different sites will be developed; a dedicated prediction model will, theoretically, improve prediction accuracy. Thirdly, genetic markers were not considered in our study because they have not been shown to be closely correlated with osteosarcoma prognosis in clinical practice. Lastly, only CT images were used in this study. In surgical planning, MRI images are indispensable because of their brilliant resolution for soft tissue. We plan to develop an additional model combining CT and MRI image features.

In conclusion, we have developed a non-invasive predictive tool, combining radiomics features and clinical risk factors, to predict survival period at the time of diagnosis in HOS cases. The developed predictive tool can also provide a basis for clinical doctors to make decisions for personalized diagnosis and treatment. Multi-center retrospective validation studies, including prospective randomized clinical trials, should be performed to obtain high-level evidence for future clinical application.
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Acknowledgements {#s0070}
================

We thank the editors and anonymous referees for their constructive comments which significantly strengthen the paper.

Funding Sources {#s0075}
===============

This work was supported by Zhejiang Provincial Natural Science Foundation of China (LR16F010001), National High-tech R&D Program for Young Scientists by the Ministry of Science and Technology of China (2015AA020917), National Key Research Plan by the Ministry of Science and Technology of China (2016YFC0104507), Natural Science Foundation of China (81,601,963, 81,201,091, 51,305,257).

Conflicts of Interest {#s0080}
=====================

We declare that we have no conflicts of interest.

Author Contributions {#s0085}
====================

Conception and design: Y·W, L·X, P·Y, T·N, Z·Y.

Collection and assembly of data: Y·W, N·L, X·H, W·P, H·L, P·L, B·L, D·Y.

Data analysis and interpretation: Y·W, L·X, P·Y, C·L, Y·J, T·N, Z·Y.

Manuscript writing: Y·W, L·X, P·Y, V·B, M·H, T·N.

Final approval of manuscript: All authors.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ebiom.2018.07.006>.

[^1]: Both authors contribute equally.

[^2]: Individual clinical factors were analyzed using Mann-Whitney U test or Chi-square test, as appropriate.

[^3]: p-value \<.05 indicates the significant difference.

[^4]: AUC: area under the curve; CI: confidence interval.
